


Hereditary angioedema (HAE)-Market Insights, Epidemiology and Market Forecast-2020



Report Introduction

DelveInsight's "**Hereditary angioedema (HAE)-Market Insights, Epidemiology and Market Forecast-2020**" Reports provides an overview of the disease and global market size of the Hereditary angioedema (HAE)-for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for hereditary angioedema (HAE) from 2011- 2020. Hereditary angioedema is a rare and potentially life-threatening disorder related with the immune system. Hereditary angioedema affects the the blood vessels. An HAE attack can result in rapid swelling of the hands, feet, limbs, face, intestinal tract, larynx (voicebox), or trachea (windpipe).

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Please note: This report requires 5-10 business days to complete. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the world from 2011-2020.
- It also provides Market size of Hereditary angioedema (HAE)for United States, EU5 and Japan from 2011 and forecasted Market size to 2020

Table of Contents

- **Hereditary angioedema (HAE)**
 - Disease overview:
 - Pathophysiology:
 - Symptoms of disease:
 - Etiology of disease
 - Diagnosis of disease
- **Treatment of disease**
- **Overview of Marketed drugs**
 - Drug Description
 - Mechanism of Action
 - Pharmacokinetics Properties
 - Marketed Details
 - Patent Information
 - Patent Exclusivity Expiry Assessment United States (US)
 - Patents Details
- **Historical and Forecasted sales of marketed drugs**
- **Global Epidemiology of Hereditary angioedema (HAE) Forecasted to 2020**
- **Epidemiology of Hereditary angioedema (HAE) & Forecasted to 2020 by 7 Major Markets (7MM)**
 - Epidemiology of United States-2020
 - Epidemiology of United Kingdom-2020
 - Epidemiology of Germany-2020
 - Epidemiology of France-2020
 - Epidemiology of Spain-2020
 - Epidemiology of Italy-2020
 - Epidemiology of Japan-2020
- **Global Market size (2011-2015)**
- **Global Forecasted Market size (2016-2020)**
- **Global Market Size by Geography**
 - Market size of US (2011-2015)
 - Forecasted Market size of US (2016-2020)
 - Market size of Europe
 - Market size of Germany (2011-2015)
 - Forecasted Market size of Germany (2016-2020)
 - Market size of United Kingdom (2011-2015)
 - Forecasted Market size of United Kingdom (2016-2020)
 - Market size of France (2011-2015)
 - Forecasted Market size of France (2016-2020)
 - Market size of Italy (2011-2015)
 - Forecasted Market size of Italy (2016-2020)
 - Market size of Spain (2011-2015)
 - Forecasted Market size of Spain (2016-2020)



- Market size of Japan (2011-2015)
- Forecasted Market Size of Japan (2016-2020)
- Market size of ROW (2011-2015)
- Forecasted Market size of ROW (2016-2020)
- **Market Analysis**
- **Market Opportunity Assessment**
- **Drivers and Barriers**
- **Appendix**
- **Report Methodology**
- **Consulting Services**
- **Disclaimer**

List of Tables

- Table 1: Drug Description
- Table 2: Drug, Marketed Details United States (US)
- Table 3: Drug, Patent Number Specific Patent Expiry in US (Year), 2015
- Table 4: Drug, Patent Details for US
- Table 5: Hereditary angioedema (HAE) Drug Sales (USD Millions), 2018
- Table 6: Global Epidemiology of Hereditary angioedema (HAE) (2011-2020)
- Table 7: Hereditary angioedema (HAE) Global Market Size (USD Millions), (2011-2015)
- Table 8: Hereditary angioedema (HAE) Global Market Size (USD Millions), (2016-2020)
- Table 9: Hereditary angioedema (HAE) US Market Size (USD Millions), (2011-2015)
- Table 10: Hereditary angioedema (HAE) US Market Size (USD Millions), (2016-2020)
- Table 11: Hereditary angioedema (HAE) United Kingdom Market Size (USD Millions), (2011-2015)
- Table 12: Hereditary angioedema (HAE) Germany Market Size (USD Millions), (2016-2020)
- Table 13: Hereditary angioedema (HAE) United Kingdom Market Size (USD Millions), (2011-2015)
- Table 14: Hereditary angioedema (HAE) United Kingdom Market Size (USD Millions), (2016-2020)
- Table 15: Hereditary angioedema (HAE) France Market Size (USD Millions), (2011-2015)
- Table 16: Hereditary angioedema (HAE) France Market Size (USD Millions), (2016-2020)
- Table 17: Hereditary angioedema (HAE) Italy Market Size (USD Millions), (2011-2015)
- Table 18: Hereditary angioedema (HAE) Italy Market Size (USD Millions), (2016-2020)
- Table 19: Hereditary angioedema (HAE) Spain Market Size (USD Millions), (2011-2015)
- Table 20: Hereditary angioedema (HAE) Spain Market Size (USD Millions), (2016-2020)
- Table 21: Hereditary angioedema (HAE) Japan Market Size (USD Millions), (2011-2015)
- Table 22: Hereditary angioedema (HAE) Japan Market Size (USD Millions), (2016-2020)
- Table 23: Hereditary angioedema (HAE) ROW Market Size (USD Millions), (2011-2015)
- Table 24: Hereditary angioedema (HAE) ROW Market Size (USD Millions), (2016-2020)

List of Figures

- Figure 1: Hereditary angioedema (HAE) Drug Sales (USD Millions), 2018
- Figure 2: Global Epidemiology of Hereditary angioedema (HAE)(2011-2020)
- Figure 3: Hereditary angioedema (HAE) Global Market Size (USD Millions), (2011-2015)
- Figure 4: Hereditary angioedema (HAE) Global Market Size (USD Millions), (2016-2020)
- Figure 5: Hereditary angioedema (HAE) US Market Size (USD Millions), (2011-2015)
- Figure 6: Hereditary angioedema (HAE) US Market Size (USD Millions), (2016-2020)
- Figure 7: Hereditary angioedema (HAE) Germany Market Size (USD Millions), (2011-2015)
- Figure 8: Hereditary angioedema (HAE) Germany Market Size (USD Millions), (2016-2020)
- Figure 9: Hereditary angioedema (HAE) United Kingdom Market Size (USD Millions), (2011-2015)
- Figure 10: Hereditary angioedema (HAE) United Kingdom Market Size (USD Millions), (2016-2020)
- Figure 11: Hereditary angioedema (HAE) France Market Size (USD Millions), (2011-2015)
- Figure 12: Hereditary angioedema (HAE) France Market Size (USD Millions), (2016-2020)
- Figure 13: Hereditary angioedema (HAE) Italy Market Size (USD Millions), (2011-2015)
- Figure 14: Hereditary angioedema (HAE) Italy Market Size (USD Millions), (2016-2020)
- Figure 15: Hereditary angioedema (HAE) Spain Market Size (USD Millions), (2011-2015)
- Figure 16: Hereditary angioedema (HAE) Spain Market Size (USD Millions), (2016-2020)
- Figure 17: Hereditary angioedema (HAE) Japan Market Size (USD Millions), (2011-2015)
- Figure 18: Hereditary angioedema (HAE) Japan Market Size (USD Millions), (2016-2020)
- Figure 19: Hereditary angioedema (HAE) ROW Market Size (USD Millions), (2011-2015)
- Figure 20: Hereditary angioedema (HAE) ROW Market Size (USD Millions), (2016-2020)

Overview of Hereditary angioedema (HAE)

Hereditary angioedema is a rare and potentially life-threatening disorder related with the immune system. HAE symptoms include episodes of oedema in various body parts including the hands, feet, face and airway. Hereditary angioedema (HAE) is caused due to defect in the gene C1 Inhibitor. Normal C1-Inhibitor helps to regulate the complex biochemical interactions of blood-based systems involved in disease fighting, inflammatory response and coagulation. The genetic defect results in production of either inadequate or non-functioning C1-Inhibitor protein.

There are 3 types of HAE Type I HAE, Type II HAE and Type III HAE. Type I HAE is defined by low plasma levels of a normal C1-INH protein reflecting an abnormality of one of the gene alleles of the protein. Type I HAE equally affects men and women. Type II HAE is characterized by the presence of normal or elevated levels of a dysfunctional C1-INH. Type II HAE also equally affects men and women. Type III HAE has no clear understanding of its pathophysiologic mechanism. The lab tests are normal, but the person has symptoms of HAE. Type III HAE occurs most often in women.


There is limited data regarding the epidemiology studies of HAE. The disease is very rare so it occurs in about 1 in 10,000 to 1 in 50,000 people.

Treatment of HAE consists of prophylaxis, management of acute attacks, and prophylactic therapy. In 2008, US Food and Drug Administration (FDA) has approved Ruconest is a C1 recombinant esterase inhibitor indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).

Global Epidemiology of Hereditary angioedema (HAE) Forecasted to 2020

DelveInsight estimates that hereditary angioedema (HAE) will grow at a rate of XXX% in the next decade. Mostly the patients are getting affected in US followed by Europe and Rest of the countries.

Figure 1: Global Epidemiology of Hereditary angioedema (HAE) (2011-2020)






Global Historical & Forecasted Market size (2011-2020)

According to DelveInsight, Global Market size of Hereditary angioedema (HAE) was \$XXX in 2011 and increased up to \$XXX million in 2020. The increased market size was majorly dependent on the XXX and XXX sales and increasing prevalence rate in major markets for hereditary angioedema (HAE)

Figure 2: Hereditary angioedema (HAE)Global Market Size (USD Millions), (2011-2020)



Region	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
United States	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
Germany	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
United Kingdom	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
France	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
Italy	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
Spain	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX
Japan	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX

Consulting Services

DelveInsight Consulting Services collaborate with Biotech & Pharmaceutical companies, Venture Capitalist, R&D Units and API Manufacturers and help them in making critical Business Decisions, Building Commercial Excellence, and Growing Businesses in an increasingly competitive and challenging environment.



Commercial: We help the client in making critical decisions by analyzing and assisting them in Brand Optimization, Portfolio Expansion, Product launch, marketing and Development Strategies.

Research & Development: We help the client in understanding the pharmaceutical markets, competitors and customers across the Pharmaceutical and Biotech industries in developed as well as emerging markets. We provide assistance in improving productivity and performance through partnerships, clinical strategies and maximizing the value creation by developing successful portfolio and asset strategies.

Operations: We help the clients in identifying business development by assisting in Mergers & Acquisition, by providing in-licensing and out licensing opportunities, due diligence and product development and lifecycle strategy.

Commercial	Research & Development	Operations
<ul style="list-style-type: none"> • Brand Optimization • Portfolio Expansion • Market Access & Development Strategies • Market Prioritization • Product Launch Assistance • Marketing & Sales 	<ul style="list-style-type: none"> • Asset Identification • Indication Prioritization • Competitive Intelligence • Competitive Landscaping • Pipeline Valuation • Reformulations [505(b)(2)] 	<ul style="list-style-type: none"> • Due Dilligence • Mergers & Acquisition • In-Licensing and Out Licensing Opportunities • Network Strategy • Franchise Protection • Product Development and Lifecycle Strategy

Disclaimer

All Rights Reserved.

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, DelveInsight.

The facts of this report were believed to be correct at the time of publication but cannot be guaranteed. Please note that the findings, conclusions and recommendations that DelveInsight delivers will be based on information gathered in good faith from both primary and secondary sources, whose accuracy we were not always in a position to guarantee.

As such DelveInsight can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect

Report Purchase Options

Buy our report instantly by mailing us at salesupport@delveinsight.com or info@delveinsight.com

You can opt for the following license options:

Report Name	Single User	Site License	Global License
Hereditary angioedema (HAE)- Market Insights, Epidemiology and Market Forecast-2020	USD 4950	USD 9900	USD 14850

About DelveInsight

DelveInsight is a Business Consultant company and serve as a Knowledge partner across the value chain of Pharmaceutical Industry. With the use of proprietary databases and analytical models, DelveInsight provides cutting-edge market and pipeline analysis and API intelligence across all therapy areas to the Pharma and biotech sector, helping clients to quantify market events and evaluate their impact on the valuation of products, portfolios and companies. Additional information is available at www.delveinsight.com.

For further information or queries, please contact the Sales Team, DelveInsight at salesupport@delveinsight.com or info@delveinsight.com